Showing results (31-40 of 71) with videos related to
Sort By:
Pageof 8
Drug Safety|February 17, 2016
Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP)Manfred Hauben, Jeffrey K Aronson, Robin E FernerDrug Safety|February 25, 2009
A strategy for regulatory action when new adverse effects of a licensed product emergeJeffrey K Aronson, Deirdre Price, Robin E FernerBritish Journal of Clinical Pharmacology|July 15, 2009
The pathophysiology of medication errors: how and where they ariseSarah E McDowell, Harriet S Ferner, Robin E FernerDrug Safety|June 28, 2012
Dose omissions in hospitalized patients in a UK hospital: an analysis of the relative contribution of adverse drug reactionsJamie J Coleman, Sarah E McDowell, Robin E FernerBritish Journal of Clinical Pharmacology|May 4, 2019
Antithrombotic dose: Some observations from published clinical trialsSimon B Dimmitt, Christopher N Floyd, Robin E FernerNature Reviews. Drug Discovery|March 31, 2012
Defining rewardable innovation in drug therapyJeffrey K Aronson, Robin E Ferner, Dyfrig A HughesClinical Toxicology (Philadelphia, Pa.)|March 26, 2019
The relationship between antemortem and postmortem morphine concentrationsNigel J Langford, Stephen R Morley, Robin E FernerDrug Safety|October 10, 2018
Preventing Future Deaths from Medicines: Responses to Coroners' Concerns in England and WalesRobin E Ferner, Tohfa Ahmad, Zainab Babatunde, et al.BMJ Case Reports|July 4, 2012
Recurrent Kikuchi-Fujimoto diseaseBrendan Boyd Spooner, Imdadur Rahman, Nigel Langford, et al.British Journal of Clinical Pharmacology|September 24, 2021
Free-of-charge medicine schemes in the NHS: A local and regional drug and therapeutic committee's experienceSimon O'Callaghan, Robin E Ferner, Andrew Barron, et al.Pageof 8